Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
devextinetug
- Development stage
- Phase 2
- Lead developer
- InterveXion Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Devextinetug (IXT-m200) is a chimeric monoclonal antibody (IgG2κ) developed by InterveXion Therapeutics for the treatment of methamphetamine use disorder and acute methamphetamine overdose. It functions as a pharmacokinetic antagonist by specifically binding to methamphetamine in the systemic circulation with high affinity and selectivity. This sequestration prevents methamphetamine from crossing the blood-brain barrier and reaching its sites of action in the central nervous system, thereby reducing its reinforcing effects and pharmacological toxicity. Devextinetug has been evaluated in multiple Phase 2 clinical trials, including the STAMPOUT and OUTLAST studies for methamphetamine use disorder and the Meth-OD study for acute overdose, demonstrating a favorable safety profile and the ability to alter the drug's volume of distribution for up to three weeks.
- Brand names
- IXT-m200IXT-m-200IXT-m 200
- Other names
- devextinetug
Beyond the preview
Go deeper on devextinetug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on devextinetug.